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T
rying to pick your way through all 
the factors that govern differential 
gene expression patterns in multi-
cellular organisms can be a tricky business. 
A quick glance at Marian Walhout’s maps 
of the interactions between transcription 
factors and DNA elements could easily 
leave one feeling more lost than ever. But 
Walhout, who constructs these maps using 
high-throughput screens and computational 
methods, successfully navigates these 
complex networks by following the trail of 
specifi  c biological questions.
Walhout’s interest in gene expression 
began as a graduate student at Utrecht 
University in the Netherlands, where she 
studied the DNA-binding properties of the 
transcription factors c-myc and max (1, 2). 
As a postdoc with Marc Vidal at Harvard 
Medical School, Walhout branched out into 
the developing fi   eld of systems biology, 
using large-scale yeast two-hybrid screens 
to map protein interaction networks in C. 
elegans (3, 4). In 2003, Walhout began her 
own laboratory at the University of Massa-
chusetts Medical School, where she turned 
her mapmaking skills back toward under-
standing transcriptional regu-
lation. Her group used yeast 
one-hybrid screens (Walhout 
calls this a gene-centered ap-
proach) to chart the protein–
DNA interactions that control 
gene transcription in worms, 
revealing some fundamental 
design principles of this regu-
latory network (5, 6). More recently, Walhout 
has expanded her focus to include the post-
transcriptional regulation of gene expression, 
exploring how micro-RNAs (miRNAs) func-
tion on a genome-wide scale (7).
In a recent interview, Walhout mapped 
out the course of her own scientifi  c career.
A GLOBAL VIEW
How do you deﬁ  ne systems biology?
Systems biology is still a relatively new 
fi  eld, so I think that there is no clear-cut 
defi  nition. The way I would phrase it is 
that rather than looking at a single gene or 
molecule, or even at a few, you really 
want to understand the relationships be-
tween different molecules, how these are 
organized into networks, and relate them 
to global phenomena that you see in the 
living system.
That sounds a little vague and abstract, 
but really, in my opinion, that’s what it is: 
asking questions that go beyond a single 
gene or protein.
How did you become a systems biologist?
My PhD was challenging. I worked on the 
transcription factors myc and max. Myc is 
one of the most insoluble proteins in the 
world—it took me about two and a half 
years to make enough soluble protein using 
vaccinia virus for DNA binding studies. It 
was frustrating to be in the cold room when 
things didn’t work. I was close to calling it 
quits, but I still loved science and wanted 
to give it another shot.
I wanted to learn more about genet-
ics, and to work with yeast. And I was 
vaguely infatuated with the human genome 
project—this was in 1996–97—although 
I didn’t quite get how it was 
going to help us. I contacted 
Marc Vidal, looking for a 
postdoc. He had these very 
ambitious, “crazy” ideas that 
I really liked, and when we 
fi   rst met and started talking 
science, I realized we thought 
in very similar ways. He’s 
been the biggest infl  uence on my career 
on many different levels, and he’s become 
one of my best friends; it’s great to talk 
with him about science and other things. 
People think we’ve been married for 50 
years. We’ll say the same thing and people 
start laughing.
The whole systems biology approach 
suited me much better, but my love for tran-
scription, which I learned in my PhD labo-
ratory, never really went away. So when I 
started my own laboratory, I was fortunate 
enough to combine the two loves into one.
Why does gene expression fascinate you?
Relatively simple multicellular organisms 
like  C. elegans have roughly the same 
number of genes as humans. We have 25,000 
genes, worms have 20,000. The greater com-
plexity of humans has to come from some-
where—one hypothesis is that transcrip-
tional and post-transcriptional regulation is 
much more complex in humans. My goal is 
to understand how turning on and off, and 
fi  ne-tuning the expression of all the genes in 
the genome makes a functioning organism. 
Right now we’re trying to understand this at 
a global level in C. elegans, and it’s fasci-
nating; there’s still very little known.
GENE-CENTERED
You describe your approach to mapping 
transcription regulatory networks as 
gene-centered. What does that mean?
Most people trying to understand transcrip-
tion at a global scale are doing ChIP—chro-
matin-immunoprecipitation. That’s a tran-
scription factor-centered approach, or protein-
to-gene: you pull down a factor, and identify a 
bunch of DNA fragments by PCR sequencing 
or microarray (ChIP-chip). It’s beautiful, but 
it does have its limitations. If you have a tran-
scription factor with a restricted expression 
pattern—maybe it’s expressed at very low 
levels or only in one or two cells of the 
worm—then ChIP isn’t technically feasible 
yet. And there aren’t enough good antibodies 
to do this on a genome-wide scale, which 
partly explains the paucity of data for 99% of 
transcription factors in the human genome.
Walhout uses the genome as a base camp for exploring 
transcriptional regulation.
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So we go the other away around. We 
start with a piece of DNA, and identify the 
transcription factors that can bind to it— 
what we call a transcription factor binding 
profi  le—using the yeast one-hybrid system. 
That goes from gene to protein.
I’m not saying that one hybrid is better 
than ChIP. I cannot stress enough that they’re 
complementary. We have limitations too: 
not everything we fi  nd is necessarily mean-
ingful in vivo and we can’t detect transcrip-
tion factor heterodimers. I think you need to 
combine approaches like these with compu-
tational biology to get to the answers.
How did you use this approach to study 
the regulation of miRNA expression?
Uri Alon has shown that there’s 
little feedback in purely tran-
scriptional networks even 
though, as biologists, we all 
know that feedback mechanisms 
are everywhere. So a talented 
graduate student in my laborato-
ry, Natalia Martinez, said “Isn’t 
that strange? I wonder if there’s 
feedback in regulatory networks 
once we incorporate miRNAs.” She set out to 
delineate an initial miRNA regulatory 
network using yeast one-hybrid. It’s a great 
example of the gene-centered approach—if 
Natalia had addressed this question by ChIP 
she would have had to immunoprecipitate all 
940 transcription factors in all conditions in 
all cells, which of course is not feasible.
We combined the miRNA regulatory 
network with a computationally derived 
network of miRNA targets. And yes—
there are many feedback loops in which 
a transcription factor regulates a miRNA, 
and is then itself regulated by that miRNA. 
It’s something that you see more often than 
you would expect by chance.
Now, this is all very cute, but then you 
think why is that? The system has evolved 
to use these loops over and over again. 
This brings you to the design principles of 
networks and I think the fi  eld of synthetic 
biology is going to be very important for 
answering those kinds of questions.
What’s harder: obtaining high-throughput 
data, or extracting meaning from it?
Well, it’s challenging to generate data because 
we always want to do more. But, for me, the 
bigger challenge is that, although I’m 100% 
an experimentalist by training, we do quite a 
bit of computation, math, and statistics in my 
laboratory. So I’m learning every day from 
the people in my laboratory, and I love it.
But, as I say to my laboratory, it’s 
important to constantly think what the ques-
tion is that you want to ask. We always try 
to relate our observations back to biologi-
cal principles and biological questions.
What advice would you give a cell biologist 
who wants to take a more systems-based 
approach to their question?
If you believe in something, then go for it. 
When we started out, people said it was 
never going to work, and I wanted to prove 
at least to myself whether it 
would or wouldn’t. And don’t 
be scared of the scale of the 
project. It’s a mindset. Working 
on a single protein can be repeti-
tive too, if you have to immuno-
precipitate it for months in a row 
to get your data. Only the scale is 
different. But once you get into 
it, it’s not such a big deal at all.
A RECIPE FOR SUCCESS
Were you tempted to return to Europe 
after your postdoc?
I came to UMass with my husband, Job 
Dekker—who is also a scientist—and it’s 
the best decision we could’ve made. On my 
very fi  rst day, I remember standing in an 
empty laboratory with my fi  rst ice bucket 
and thinking, “Wow, this system has enough 
belief in us and what we want to do that it 
gives us a bunch of money and space, and 
then says: go do it.” It’s very unusual to get 
such an opportunity in Europe, and I think 
that really makes the United States special.
And UMass is a special place too. 
The science is fantastic and we have a 
wonderful cohort of collaborative, friendly 
colleagues. When Job and I started here, 
I used to say about once a week, “I think 
UMass is the best-kept secret in science,” 
but I think the secret is out now.
What are your hobbies?
I love cooking for people and trying out 
new dishes. My friends enjoy my food.
Are you an experimenter in the kitchen, 
or do you strictly follow the recipe?
Oh, no, I’m an experimenter, just like in 
science. I say to my students that you fi  rst 
have to follow the protocol and make sure 
it works, and then you can try to improve 
it. Not the other way around; that’s usually 
not a good idea!
What’s next for you?
We want to do a much larger study in C. 
elegans, to interrogate parts of the genome 
other than promoters. We want to understand 
the relative importance of promoters versus 
introns and other sequences, and, with our 
approach, we can address those questions 
because we start from the genome.
And another thing that I really want to 
start doing is human studies. I didn’t want to 
begin with human because people can be ner-
vous about these types of global approaches, 
and we really wanted to leverage the power 
of a genetically tractable metazoan like C. 
elegans to follow up on the data that we got.
But now we know how the yeast one-
hybrid system behaves, so we’re ready to 
start the much more daunting task of inter-
rogating the human genome. The human 
genome is 30 times bigger, with large in-
trons and intergenic regions, so it’s much 
less clear where you need to look.
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